The rise of superbugs is a global health issue and one of the leading threats to human health today according to the World Health Organisation.
Our portfolio of new antibiotic therapies holds the potential to address the major threat to human health posed by drug resistant bacteria.
Our lead candidate RECCE®327 is designed as abroad-spectrum antibiotic, formulated using synthetic polymer technology to treat bacterial sepsis (blood poisoning) and other bacterial infections, including superbugs.
Recce Pharmaceuticals Ltd is currently in discussions with the US Food & Drug Administration (FDA) as it seeks approval to test its therapy in humans.
The Social and Economic Cost of Antibiotic Resistance
Antibiotic resistance currently accounts for an estimated 50,000 deaths in the US and Europe. The estimated current death toll worldwide is 700,000.
If antibiotic resistance were allowed to grow unchecked, the number of deaths per year would grow to 10 million by 2050. That is more than the 8.2 million per year who currently die of cancer and 1.5 million who die of diabetes, combined; costing the world up to 3.5 percent of its total gross domestic product, or up to US$100 trillion by 2050.